What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce Abbott Laboratories' financial results for the third quarter of 2020 and to provide investors with access to the official press release containing these results.

What are non-GAAP financial measures, and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) figures. Abbott uses them to provide a clearer picture of its ongoing operational performance by excluding items like acquisition costs, restructuring charges, and certain tax adjustments that are considered unusual or unpredictable. Management believes these measures help investors better evaluate the company's underlying business performance.

Where can I find the detailed Q3 2020 financial results?

The detailed Q3 2020 financial results are available in the press release furnished as Exhibit 99.1 to this 8-K filing. Investors are encouraged to review this press release for comprehensive information.

Does Abbott recommend investors focus solely on non-GAAP measures?

No, Abbott cautions investors to consider its non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP. This means investors should look at both GAAP and non-GAAP figures for a complete understanding of the company's financial health.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on October 21, 2020, to announce its financial results for the third quarter of 2020. The filing primarily references a press release (Exhibit 99.1) that details these results. Investors should note that Abbott utilizes non-GAAP financial measures in its reporting, which exclude certain specified items such as acquisition and restructuring expenses, R&D asset acquisition costs, asset impairments, litigation settlements, and various tax-related adjustments and benefits. These non-GAAP measures are presented to provide a clearer view of ongoing operational performance, as management believes they better reflect the company's underlying business trends and are used internally for performance assessment.

Key Highlights

1Abbott Laboratories announced its Q3 2020 financial results on October 21, 2020, via an 8-K filing.
2The 8-K filing incorporates by reference a press release detailing the Q3 2020 financial performance.
3The company utilizes non-GAAP financial measures, such as net earnings excluding specified items, for reporting.
4Non-GAAP measures are adjusted for unusual or unpredictable items including acquisition/restructuring costs and litigation settlements.
5Intangible amortization expense is also excluded in non-GAAP reporting to enhance visibility into ongoing operations.
6Abbott's management believes these non-GAAP measures offer valuable insights for investors to assess underlying business performance.
7The filing includes the CFO's signature, Robert E. Funck, Jr., indicating an official release of financial information.

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 21, 2020)

Summary

Key Highlights

Frequently Asked Questions